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Epstein-Barr virus (EBV) was the first human virus proved to be closely associated with tumor development, 
such as lymphoma, nasopharyngeal carcinoma (NPC) and EBV-associated gastric carcinoma. Despite many 
efforts to develop prophylactic vaccines against EBV infection and diseases, no candidates have succeeded in 
effectively blocking EBV infection in clinical trials. Previous investigations showed that EBV gp350 plays a 
pivotal role in the infection of B lymphocytes. Nevertheless, using monomeric gp350 proteins as antigens has 
not been effective in preventing infection. Multimeric forms of the antigen are more potently immunogenic than 
monomers, however the multimerization elements used in previous constructs are not approved for human 
clinical trials. To prepare a much-needed EBV prophylactic vaccine that is potent, safe and applicable, we 
constructed an Fc-based form of gp350 to serve as a dimeric antigen. Here we show that the Fc-based gp350 
antigen exhibits dramatically enhanced immunogenicity compared to wild-type gp350 protein. The complete or 
partial gp350 ectodomain was fused with the mouse IgG2a Fc domain.  Fusion with the Fc domain did not 
impair gp350 folding, binding to a conformation-dependent neutralizing antibody and binding to its receptor by 
ELISA and SPR. Specific antibody titers against gp350 were notably enhanced by immunization with gp350-Fc 
dimers compared to gp350 monomers. Furthermore, immunization with gp350-Fc fusion proteins elicited potent 
neutralizing antibodies against EBV. Our data strongly suggest that an EBV gp350 vaccine based on Fc fusion 
proteins may be an efficient candidate to prevent EBV infection in clinical applications. 
 
Figure 1. Immunization with Fc fusion 
antigens potently induced production 
of neutralizing antibodies. (A) 
Diagrams for design of Fc-based 
recombinant gp350 proteins. (B) 
Diagram of the immunization 
protocols. Mice were boosted on week 
2 for i.n. group or week 3 for i.p. group. 
(C) Neutralization of EBVGFP infection 
by sera collected at week 5 post-
immunization. Recombinant EBVGFP 
was preincubated with 10× or 40× 
dilutions of sera from mice immunized 
with the indicated antigens. Virus was 
added to Akata cells and GFP 
fluorescence was recorded as a 
measure of infection. 
 
